Previous 10 | Next 10 |
home / stock / esalf / esalf news
TOKYO, July 19, 2019 - (JCN Newswire) - Eisai Co.,Ltd. announced the presentation and discussion about the treatment, including oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat(1) research data on Alzheimer's disease(AD), were given in the AAIC's Focused Topic Session "Discussio...
In Cerebrospinal Fluid and the Identification of a Target Engagement Biomarker for the New Anti-Tau Antibody E2814 at Alzheimer's Association International Conference (AAIC) 2019 TOKYO, July 19, 2019 - (JCN Newswire) - Eisai Co.,Ltd. announced that data relating to a new anti-tau antibody E2...
TOKYO, July 18, 2019 - (JCN Newswire) - Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with ...
Without Significant Effects on Synaptic Function in Brain by Spinal Densitiy Evaluation at Effective Dose to Decrease Amyloid Beta Level in Cerebrospinal Fluid at Alzheimer's Association International Conference (AAIC) 2019 TOKYO, July 18, 2019 - (JCN Newswire) - Eisai Co.,Ltd. announced its...
TOKYO, July 17, 2019 - (JCN Newswire) - Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy...
An Index for Socially Responsible Investment Eisai TOKYO, July 11, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 18th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index ...
TOKYO, July 11, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 13 presentations containing two oral presentations including the latest data of the anti-amyloid beta (A beta) protofibril antibody BAN2401 and the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbec...
A Focused Drug Discovery Approach That Integrates Human Genetics/ Data Science/ Precision Chemistry TOKYO, July 10, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Ma...
TOKYO, July 8, 2019 - (JCN Newswire) - Eisai Co.,Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)(1) toward drug discovery in oncology area. PROTACs consist of two covalently linked protei...
Derived From Total Synthesis of Halichondrin Found in Joint Research Between Eisai and Harvard University Scientists, Published in Scientific Reports TOKYO, June 18, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that a joint research group including scientists from Eisai and Profes...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMB...
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong TOKYO and CAMBRIDGE, Mass., July 11, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated ...
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...